A senate panel on Tuesday grilled AbbVie Chairman and CEO Richard Gonzalez about the U.S. drugmaker's arthritis treatment Humira, saying that tying executive bonuses to sales of the blockbuster drug was"problematic." Humira's $18.3 billion in 2017 sales — which rose 14.6 percent from the previous year and accounted for about 65 percent of the company's $28.
, said in questioning the CEO at a hearing on prescription drug costs before the Senate Finance Committee on Tuesday."Would you make a smaller bonus if you dropped the price of Humira?" In response, Gonzalez said,"Humira was one element of a set of financial factors that were evaluated as part of my compensation. It's obviously a very significant product for us. So it is clear it would be a part of the evaluation.
While at PFE, tried 2X unsuccessfully to partner on Humira sales; 1st w/German biotech & w/Abbott. Humira CEO salient- replaced Lipitor as 1 in global sales.. - Sen. panel grills pharma on CEO bonuses. Ties to blockbuster Humira sales called 'problematic'
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Why Abbvie May Have A Tough Time Defending Humira's Price Before CongressDrug maker Abbvie may have to defend the price of its Humira treatment before the U.S. Senate Finance Committee today. 🥶 i don't know who else to tag to get this msg to Faiza Beauty CareemPAK
Source: Forbes - 🏆 394. / 53 Read more »
Why Abbvie May Have A Tough Time Defending Humira's Price Before CongressDrug maker Abbvie may have to defend the price of its Humira treatment before the U.S. Senate Finance Committee today. The company was fighting in court to keep the biosimilar, Amjevita, approved by the FDA from being sold in the U.S. market. Just saw they settled at the end of January. Undisclosed. Interesting timing. A great example of a CEO who should be in prison
Source: Forbes - 🏆 394. / 53 Read more »